StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) Reports First Patient Enrollment in Phase 3b Study to Evaluate Extended Interval Dosing with Natalizumab in Multiple Sclerosis
January 3, 2019 7:31 AM
The first patient has been enrolled in a global Phase 3b study evaluating the efficacy and safety of extended interval ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Biogen (BIIB) Reports Strategic Collaboration with Skyhawk Therapeutics to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
January 4, 2019 7:32 AM
Biogen (BIIB) Reports Strategic Collaboration with C4 Therapeutics to Discover and Develop Potential New Treatments for Neurological Conditions
January 4, 2019 7:31 AM
First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis
January 3, 2019 7:30 AM
